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Objective: Chronic Subdural Hematoma (cSDH) is primarily a disease of elderly, and is
rare in patients <50 years, and this may in part be related to the increased brain atrophy
from 50 years of age. This fact may also influence clinical presentation and outcome. The
aim of this study was to study the clinical course with emphasis on clinical presentation
of cSDH patients in the young (<50 years).
Methods: A retrospective review of a population-based cohort of 1,252 patients
operated for cSDH from three Scandinavian neurosurgical centers was conducted.
The primary end-point was difference in clinical presentation between the patients
<50 y/o and the remaining patients (≥50 y/o group). The secondary end-points were
differences in perioperative morbidity, recurrence and mortality between the two groups.
In addition, a meta-analysis was performed comparing clinical patterns of cSDH in the
two age groups.
Results: Fifty-two patients (4.2%) were younger than 50 years. Younger patients were
more likely to present with headache (86.5% vs. 37.9%, p < 0.001) and vomiting (25%
vs. 5.2%, p < 0.001) than the patients ≥50 y/o, while the ≥50 y/o group more often
presented with limb weakness (17.3% vs. 44.8%, p < 0.001), speech impairment (5.8%
vs. 26.2%, p = 0.001) and gait disturbance or falls (23.1% vs. 50.7%, p < 0.001). There
was no difference between the two groups in recurrence, overall complication rate and
mortality within 90 days. Our meta-analysis confirmed that younger patients are more
likely to present with headache (p = 0.015) while the hemispheric symptoms are more
likely in patients ≥50 y/o (p < 0.001).
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Conclusion: Younger patients with cSDH present more often with signs of
increased intracranial pressure, while those≥50 y/o more often present with hemispheric
symptoms. No difference exists between the two groups in terms of recurrence,
morbidity, and short-term mortality. Knowledge of variations in clinical presentation is
important for correct and timely diagnosis in younger cSDH patients.
Keywords: chronic subdural hematoma, young, neurosurgery, symptoms, clinical course, morbidity, mortality,
meta-analysis
INTRODUCTION
Chronic subdural hematoma (cSDH) is a diagnosis with
increasing prevalence among the older. Nevertheless, cSDH is
also seen in younger patients (previously defined as <50 years
in literature), although less commonly (1–5). And while cSDH
in the young is often associated with predisposing condition
i.e., arachnoid cysts, coagulation disorders, or ventriculo-
peritoneal shunts, even cSDH without predisposing condition
has been reported, often in connection with head trauma (6, 7).
Correct interpretation of clinical presentation is important for
timely diagnosis. Nevertheless, the reports from literature on
the clinical presentation of younger patients with cSDH are
varied and often conflicting (1–5). Also, even though surgical
evacuation is the main treatment modality in cSDH patients,
little is known as to the recurrence rates, morbidity and
mortality of young patients with surgically treated cSDH. A
large-scale, population-based multicenter study is warranted to
benchmark the clinical course and outcome of younger patients
with cSDH.
In this population-based multicenter study of adult patients
with cSDH, we assessed the clinical course and outcome in




Adult patients (≥18 years old) with a cSDH (defined as
hypodensity, hyperdensity, and/or combined hypo- and hyper-
density on computed tomography (CT) treated with burr hole
evacuation between January 1, 2005 and December 31, 2010
at the departments of Neurosurgery at St. Olavs University
Hospital (Trondheim, Norway), Karolinska University Hospital
(Stockholm, Sweden) and the University Hospital of North
Norway (Tromsø, Norway) were included. Patients operated
intracranially within the past 6 months, patients with ventriculo-
peritoneal shunts, with cSDH in relation to arachnoidal
cysts were excluded. The Nordic health care system with
regional referral practice to neurosurgical centers ensures a
representative population-based study, with data gathering for
this database done by experienced medical staff. As reported
previously, there was no differences between regions in the
age and sex adjusted incidence rates (p = 0.096, data not
shown) (8).
Treatment Characteristics
Diagnosis was ascertained by a computed tomography (CT)
and/or magnetic resonance imaging (MRI) in all patients.
Anticonvulsants were not routinely administered unless the
patient has experienced convulsions. cSDH evacuation was
performed according to local practice (8). At all centers taking
part in the study, surgery was offered to all patients with
symptomatic cSDH as first-line treatment regardless of age.
Study and Outcome Variables
According to previously calculated (9) age-adjusted incidence
rates for the different age groups the incidence is very low,
0.6/100.000 among patients 18–49 y/o, while this rise to
7.1/100.000 (50–66 y/o) and up to 59.5/100.000 (80–89 y/o). This
information together with knowledge of brain atrophy increasing
after 50 years of age (10), and that this age group of 18–49
years old was <5% of our population-based cohort argued for
a “younger group” aged 18–49 years old.
Data collection for this manuscript was done by experienced
medical staff using the electronic patient records at each center,
with data quality confirmed by the principal investigator based
upon quality control. End of follow-up was 01.01.2012, thus all
patients were followed at least 1 year or until death. Recurrence
was defined as same-sided chronic subdural hematoma within 6
months following index surgery. Patient characteristics included
data on the pre-operative status including comorbidity and
residential situation (home without assistance, home care and
institution) (11), Radiology characteristics included hematoma
location (right, left, and bilateral), density (hypodense, mixed,
isodens, and hyperdens) and midline shift. Further, the radiology
was reviewed to ensure that no apparent bleeding source (such as
an AVM, fistula, tumor etc.) was present in any of the included
patients, nor did any included patient have any structural
abnormalities. Also, upon review, the younger group did not
have any signs of early atrophy. Adverse events within 30 days
were classified according to Landriel Ibanez et al. (12), with
severe morbidity classified as Landriel grade III. Mortality was
assessed at 1 and 3 months. Recurrent cSDH was defined as any
same-sided cSDH treatment within 6 months of index surgery.
Overall recurrence and survival were illustrated by Kaplan-
Meier analysis and compared with log-rank test. According to
protocol, we evaluated recurrence up to 6 months after surgery
as done by others (13), since most recurrences occur early and
a longer time-span would increase chance of including de novo
cases rather than treatment failures. We had 6 months follow-up
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on all patients, however in the analysis of overall survival patients
were censored at end of follow up if still alive.
Meta-Analysis
Systematic review of literature and meta-analysis was performed
to determine if differences exist between <50 y/o and
≥50 y/o patients with subdural hematoma in terms of sex,
medical history, presenting symptoms, imaging findings, and
complication rates. The cut off age was chosen as 50 years for the
meta-analysis except for 4 studies with 40 and 45 years as the cut
off age (these were included due to their large cohort size).
The meta-analysis was performed in accordance with the
Preferred Reporting Items for Systematic Reviews and Meta-
Analysis (PRISMA) guidelines (14). A comprehensive PubMed
database search was conducted on May 17th, 2018 using the
term (subdural hematoma OR SDH) [Title/Abstract] AND
(young∗ OR elderly∗ OR adult∗ or age groups∗ OR comparison)
[Title/Abstract] (Figure 1).
Articles were included if they: (1) were written in English
(or an English translation was available), (2) involved human
subjects, (3) were fully published peer-reviewed clinical articles,
(4) had at least an abstract available, (5) included a comparison
of the younger and older patients with cSDH. Case reports,
articles related to basic sciences and other operative techniques in
stereotaxy; editorials, commentaries, or conference proceedings
were excluded. The literature search was not restricted by
the date of publication of the articles. In the meta-analysis,
hemispheric symptoms were defined as occurrence of sensory
or motor deficit, gait disturbance, speech impairment, mental
status change, or seizure. Bleeding tendency was considered
to be present if the patient was on anti-platelets or anti-
coagulation therapy, or with a hematologic disorder or
liver disease.
Statistical Analysis
SPSS version 24.0 (SPSS, Inc., Chicago, IL, USA) was used
for analysis, while the meta-analysis was performed using
Comprehensive Meta-Analysis software (Version 3.3070,
BioStat, Englewood, NJ, USA). Significance was defined as P <
0.05, with no adjustments for multiple comparisons. Continuous
variables were analyzed using an unpaired two-tailed t-test
for normally distributed data. Continuous data with skewed
distribution were analyzed with the Mann-Whitney U-test.
Discrete variables were compared using a Chi-square analysis.
The meta-analysis was done by pooling results using a random-
effects model. Heterogeneity was categorized as low (25–50%),
moderate (50–75%), or high (>75%) (15). Publication bias was
evaluated using funnel plots, Egger’s regression intercept test,
and Duval and Tweedie’s trim and fill test (16, 17).
RESULTS
One thousand two hundred and fifty two patients operated for
cSDH were included. We identified 52 patients (4.2%) with
FIGURE 1 | PRISMA Flow Diagram for search strategy and literature selection.
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primary operations for cSDH evacuation in younger patients
aged 49 or less (<50 y/o group). The median age in the respective
age groups was 40.9 years in the younger group and 75.4 years
in the ≥50 y/o group. The median follow-up time (from surgery
until end of follow-up) was 42 months in the younger group and
43 months in the ≥50 y/o group.
Younger patients presented more often with headache (86.5%
vs. 37.9%, p < 0.001) and vomiting (25.0% vs. 5.2%, p < 0.001),
while the patients ≥50 y/o more often presented with limb
weakness (17.3% vs. 44.8%, p < 0.001), speech impairment (5.8%
vs. 26.2%, p = 0.001) and gait disturbance or falls (23.1% vs.
50.7%, p < 0.001). No difference between groups was seen with
respect to cognitive deterioration, acute confusion, drowsiness
or coma, seizures, incontinence and/or visual disturbances. See
Table 1 for further details.
Compared to the patients ≥50 y/o, the younger patients had
less comorbidities (13.5% vs. 34.6%, p = 0.002), were more
independent (p < 0.001) and used less anti-platelets (1.9% vs.
28.1%, p < 0.001) and anti-coagulants (5.8% vs. 17.9%, p =
0.02). Pre-operatively, younger patients had on average a smaller
hematoma diameter (18mm vs. 22mm, p < 0.001), but midline
shift was similar. Younger patients were less often operated with
local anesthesia and sedation only (84.6% vs. 94.7%, p = 0.002).
See Table 2 for further details.
Outcome
Younger patients had more often a clinical (p = 0.002) and/or
radiological (p = 0.005) follow-up after surgery. No difference
between groups was seen with respect to recurrence (Figure 4)
and complications (Table 3). There was a difference in overall
survival between groups (p = 0.002, Figure 5). See also Table 3
for further details.
Meta-Analysis Results With <50 Years as
Cut-Off
Fourteen studies including the current study were included in
the meta-analysis (4, 18–32). Date of publication ranged from
1979 to 2018. Among a total of 2,440 patients, 282 were classified
as younger (<50 y/o). Cohort size, male sex, headache,
TABLE 1 | Clinical presentation in patients with cSDH <50 y/o vs. ≥50 y/o.
Characteristics 18-49 y/o
n = 52 (%)
≥50 y/o
n = 1,200 (%)
p-value
Limb weakness 9 (17.3) 538 (44.8%) <0.001
Headache 45 (86.5%) 455 (37.9%) <0.001
Speech impairment 3 (5.8) 314 (26.2%) 0.001
Gait disturbance or falls 12 (23.1) 608 (50.7) <0.001
Cognitive deterioration 8 (15.4) 283 (23.6) 0.17
Acute confusion 6 (11.5) 251 (20.9) 0.10
Drowsiness or coma 6 (11.5) 197 (16.4) 0.35
Seizure 1 (1.9) 37 (3.1) 0.63
Incontinence 0 55 (4.6) 0.11
Visual disturbances 1 (1.9) 20 (1.7) 0.89
Vomiting 13 (25.0) 62 (5.2) <0.001
nausea/vomiting, hemispheric symptoms, papilledema,
recurrence, history of trauma, and hematoma thickness are
summarized for each group (Supplementary Tables 1, 2).
Younger patients are significantly more likely to present with
headache (p = 0.015) while the hemispheric symptoms are more
likely to be experienced by the patients ≥50 y/o (p < 0.001,
Figure 2).
No statistical differences were found concerning hematoma
thickness (p = 0.08) or nausea/vomiting (p = 0.11), gender (p
= 0.74), recurrence rate (p= 0.51), history of trauma (p= 0.77),
and bleeding tendency (p= 0.55) between age groups (Figures 2,
3). No publication bias was noted among the included studies for
any variable as is evident from the gross symmetry of the funnel
plots (Supplementary Figures S1, S2).
TABLE 2 | Baseline and per-operative characteristics in patients with cSDH <50
y/o vs. ≥50 y/o.
Characteristics 18–49 y/o
n = 52 (%)
≥50 y/o
n = 1,200 (%)
p-value
Median age, years (SD) 40.9 (6.7) 75.4 (10.4) <0.001
Mean follow-up in
months (SD)
42 (21) 43 (19) 0.65
Sex male 37 (71.2) 835 (69.6) 0.81
CCI* >1 7 (13.5) 415 (34.6) 0.002
Bilateral surgery
(missing, n = 3)




33 (66.0) 830 (74.6) 0.18
Largest diameter mean
mm (SD)
18.0 (6.0) 22.0 (6.2) <0.001
Midline shift, mean mm
(SD)
8.5 (5.1) 7.7 (4.7) 0.24
GCS** in categories 0.38
13–15 49 (94.2) 1061 (89.8)
9–12 3 (5.8) 82 (6.9)




1 (1.9) 337 (28.1) <0.001
Anticoagulants
Missing 2
3 (5.8) 215 (17.9) 0.02
Home w/o care 51 (98.1) 880 (73.3) <0.001
Home with support 1 (1.9) 205 (17.1)
Institution 0 110 (9.4)
Surgical procedure <0.001
Passive drain 13 (25.0) 323 (26.9)
Continuous 5 (9.6) 141 (11.8)
Subgaleal/subperiostal 30 (57.7) 729 (60.8)
Burrhole without
drainage




44 (84.6) 1,133 (94.7) 0.002
*Charlson Comorbidity Index. **Glasgow Coma Scale.
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FIGURE 2 | Forest plots of headache (A), nausea and vomiting (B), hemispheric symptoms (C), and recurrence rate (D) assessed in meta-analysis (≤50 years as age
cut-off). Squares and horizontal bars indicate point estimate and 95% confidence intervals of odds ratio/standardized difference in means in each study, respectively.
Diamonds indicate the summary estimates that are calculated as per random effects model.
DISCUSSION
This multicenter, population-based study is to the best of our
knowledge the largest cohort study in literature on young
patients with cSDH, demonstrating that younger patients (<50
y/o) with cSDH present more often with signs of increased
intracranial pressure, while patients ≥50 y/o more often present
with neurological deficits. Patients <50 y/o have similar rates of
recurrence and perioperative morbidity as compared to patients
≥50 y/o. The diversity in clinical presentation depending on
patient age is important for correct and timely diagnosis of
cSDH. And although a head scan should be considered in cases
of persisting signs of headache, nausea and vomiting without
neurological deficits in young adults, one needs to keep in mind
the incidence of post-concussion syndrome which is 50% at 1
month and 15% at 1 year when assessing patients (33). Further,
to the best of our knowledge, we have conducted the first meta-
analysis to compare the clinical pattern in patients <50 y/o vs.
≥50 y/o with cSDH.
Baseline and Per-Operative Characteristics
The baseline characteristics between groups did not differ
significantly except from the younger having less comorbidities,
being more independent and using less of both anti-platelets
and anticoagulants. Despite increased use of antiplatelet and
anticoagulant drugs in the patients ≥50 y/o, the meta-analysis
suggests no significant increase in bleeding tendency in this
age group.
Between 50 and 80 years of age, it has been shown that the
weight of the brain decreases approximately 200 grams (34).
Further, the space between the brain and skull increases from 6 to
11% of the total intracranial space (35). As such, this offers greater
space for a hematoma to expand without necessarily increasing
the intracranial pressure (2, 4). We and others have observed
larger on average hematoma diameter in the patients ≥50 y/o,
which is logical from a biological point of view. This is even
substantiated by the fact that there were 7.7% of younger patients
operated with burr hole only (compared to 0.6% of patients
≥50 y/o patients), since the lack of subdural “space” and early
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FIGURE 3 | Forest plots of male sex (A), history of trauma (B), bleeding tendency (C), and hematoma thickness (D) assessed in meta-analysis (≤50 years as age
cut-off). Squares and horizontal bars indicate point estimate and 95% confidence intervals of odds ratio/standardized difference in means in each study, respectively.
Diamonds indicate the summary estimates that are calculated as per random effects model.
brain realignment prevented any drainage being placed. Finally,
probably due to the increased risk of adverse events associated to
the use of general anesthesia in older patients, local anesthesia +
sedation was the preferredmethod of per-operative sedation (36).
Clinical Presentation
The clinical presentation was dominated by signs/symptoms of
raised intracranial pressure in the patients<50 y/o; headache and
vomiting—both which has been previously reported by others
as being the cardinal symptoms in young patients with cSDH
(1, 2, 4, 5). This is likely explained by a mass effect without
significant age-related atrophy, in line with findings that age up to
49 years had no significant influence on the weight of the human
brain (10). Thus, symptoms arrive earlier (smaller hematomas)
and apparently before neurological deficits occur in most cases,
but the midline shift is similar between age groups.
Our findings are consistent with the existing literature
as evident from the meta-analysis results, with the younger
population more likely to present with headache, and nausea and
vomiting, in contrast to the hemispheric symptoms which are
more commonly a finding in patients ≥50 y/o.
Outcome
Similar recurrence rate for cSDH was observed in our study
consistent with the meta-analysis results. In the present study,
clinical and radiological post-operative controls were less
frequently undertaken in the patients ≥50 y/o—which is in line
with our belief that there might be a higher threshold to diagnose
patients ≥50 y/o, and especially the very old may more often be
institutionalized to begin with.
The frequency of adverse events correlated to surgical
treatment of cSDH in the younger has been reported to be
similar when compared to older or even those extremely old
(4, 9), although adverse events are generally seldom reported
at all in series concerning the young cSDH patients (2). In
our material, although non-significant, patients ≥50 y/o had a
higher frequency of overall complications (9.0% vs. 3.8%) than
the patients<50 y/o. This becomes even more evident when only
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FIGURE 4 | Kaplan-Meier plot illustrating recurrence (p = 0.64).
TABLE 3 | Outcome in patients with cSDH <50 y/o vs. ≥50 y/o.
Characteristics 18–49 y/o
n = 52 (%)
≥50 y/o








36 (69.2) 546 (47.2) 0.002
Recurrence 8 (15.4) 161 (13.4) 0.68
Overall complication 2 (3.8) 108 (9.0) 0.20
Complication Landriel
grade ≥3
0 37 (3.1) 0.20
Mortality 30 days
Missing 2
0 42 (3.5) 0.17
Mortality 90 days
Missing 2
1 (1.9) 76 (6.3) 0.19
looking at serious adverse events (defined as Landriel grade ≥3)
which only occurred among the patients ≥50 y/o (n= 37, 3.1%).
With respect to mortality, it has been reported in literature
that cSDH in the old may reveal and/or exacerbate underlying
medical condition leading to poor outcome, a so-called “sentinel
health event” as described by Miranda et al. (37), which also
demonstrated a lower functional status in older patients at
discharge, than when they were first admitted. Nevertheless,
we found no significant difference in 30 and 90 days mortality
between groups, although a difference in overall survival was
noted (p= 0.002).
Strengths and Limitations
Limitations and potential sources of bias associated with
retrospective data analysis are present in the current study.
Another limitation is the lack of etiological data as well as
FIGURE 5 | Kaplan-Meier plot illustrating overall survival (p = 0.002).
long-term follow-up data and functional status postoperatively.
Nevertheless, our series represents the largest consecutive series
of patients <50 y/o operated for cSDH, with a population-based
setting making it less at risk of selection bias. Also, our study
only takes into account recurrences leading to reoperation—
which might have introduced bias in terms of detection
and selection.
Further, we have conducted the first meta-analysis comparing
clinical profile of patients <50 y/o vs. patients ≥50 y/o with
cSDH. The pooled sample size was considerable, with 2,440
patients from 14 studies, which increased the power of our study.
No obvious publication bias were detected which added to the
reliability of this analysis. Presence of a significant heterogeneity
between the included studies is one of the limitations of
our study.
CONCLUSION
In this multicenter, population-based study of patients with
cSDH, supplemented by a meta-analysis based on current
literature, we demonstrate a significant difference in clinical
presentation of patients <50 y/o vs. patients ≥50 y/o with
cSDH. Also, we demonstrate comparable morbidity-, recurrence-
and peri-operative mortality rates between groups. It seems
reasonable to conclude that attention to clinical presentation is
crucial for timely diagnosis of patients with cSDH.
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Supplementary Figure S1 | Funnel plots for headache (A), nausea and vomiting
(B), hemispheric symptoms (C), and recurrence rate (D) demonstrating gross
symmetry. Blue circles: observed studies, Red plot: plot for both observed and
imputed studies from Duval and Tweedie’s trim and fill analysis.
Supplementary Figure S2 | Funnel plots for male sex (A), history of trauma (B),
bleeding tendency (C), and hematoma thickness (D) demonstrating gross
symmetry. Blue circles: observed studies, Red plot: plot for both observed and
imputed studies from Duval and Tweedie’s trim and fill analysis.
Supplementary Table 1 | Characteristics of studies with patients with cSDH in
the patients <50 y/o age. –, Not reported, ∗current study.
Supplementary Table 2 | Characteristics of studies with patients with cSDH in
the patients ≥50 y/o age. –, Not reported, ∗current study.
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